UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15 (d) OF
THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): February 27, 2007
MYLAN LABORATORIES INC.
(Exact name of registrant as specified in its charter)
| |
|
|
|
|
| Pennsylvania
|
|
1-9114
|
|
25-1211621 |
(State or other jurisdiction
of Incorporation)
|
|
(Commission File
Number)
|
|
(I.R.S. Employer
Identification No.) |
1500 Corporate Drive
Canonsburg, PA 15317
(Address of principal executive offices)
(724) 514-1800
(Registrant’s telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy
the filing obligation of the registrant under any of the following provisions:
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange
Act (17 CFR 240.14d-2 (b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange
Act (17 CFR 240.13e-4 (c))
Item 8.01. Other Events.
On February 27, 2007, Mylan Laboratories Inc., a Pennsylvania corporation (the “Company”),
issued a press release reporting that the district court for the Western District of Pennsylvania
had ruled in favor of Pfizer in the Company’s pending amlodipine litigation and that the Company
plans to immediately appeal the ruling. The Company also announced
that it reaffirmed its fiscal 2007 adjusted earnings per diluted share guidance of $1.50 to $1.55 as this product was never factored into the Company's fiscal 2007 guidance.
A
copy of the press release is attached hereto as Exhibit 99.1 and is
incorporated herein by reference.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
| |
|
|
Exhibit No.
|
|
Description |
|
|
|
99.1
|
|
Press Release of the registrant dated February 27, 2007. |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly
caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| |
|
|
|
|
|
| |
|
MYLAN LABORATORIES INC. |
|
|
|
|
|
|
|
|
|
|
Date: February 27, 2007
|
|
By:
|
|
/s/ Edward J. Borkowski |
|
|
|
|
|
|
|
|
|
Edward J. Borkowski
Chief Financial Officer |
2